Drug Profile

Tegavivint - Apollomics/Iterion Therapeutics

Alternative Names: APL-121; BC-2059; Tegatrabetan - Iterion therapeutics

Latest Information Update: 03 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BetaCat Pharmaceuticals
Developer Apollomics; Iterion Therapeutics; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center
Class Anthracenes; Antineoplastics; Hydroxylamines; Nitroso compounds; Piperidines; Small molecules; Sulfonamides
Mechanism of Action Beta catenin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Fibroma
New Molecular Entity Yes

Phase II Fibroma
Phase I/II Liver cancer; Solid tumours
Phase I B-cell lymphoma
Preclinical Acute myeloid leukaemia; Lymphoma; Non-small cell lung cancer; Osteosarcoma
No development reported Multiple myeloma

27 Aug 2025 Emory University in collaboration with Iterion Therapeutics plans a phase I trial for Osteosarcoma (Second-line therapy or greater, Combinantion therapy, In infants, In children, In adolescents, In adults) (IV, Infusion) in October 2025 (NCT07144254)
25 Apr 2025 Efficacy and adverse events data from a phase-I/II trials in Liver cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
28 Jan 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com